オメガ3処方薬の世界市場レポート 2025年

オメガ3処方薬市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.3％で26億1,000万米ドルに成長します。予測期間の成長は、適応症の拡大、消費者の嗜好の進化、ターゲットを絞った健康ソリューション、個別化医療、臨床エビデンスの拡大に起因しています。予測期間の主な動向には、個別化された健康ソリューション、健康状態の拡大、革新的な製剤、健康サプリメントの普及、健康アプリ、ウェアラブルなどがあります。

心血管疾患（CVD）の有病率の増加は、オメガ3処方薬市場の成長を後押しすると予想されます。脂肪物質である血中トリグリセリド濃度の上昇は、心血管障害のリスク上昇と関連しており、オメガ3サプリメントはこれらのトリグリセリド濃度を調整し低下させるのに役立ちます。例えば、世界保健機関（WHO）が2022年に発表した報告によると、心血管疾患は依然として世界の死因の第1位であり、死亡者数は約2,050万人、死亡者数全体のほぼ3分の1を占めています。これは、以前に推定されたCVDによる死亡者数1億2100万人から増加したことを意味します。その結果、心血管疾患の罹患率が上昇し、オメガ3処方薬市場の拡大を牽引しています。

肥満と闘う人口の拡大は、オメガ3処方薬市場の成長に大きく貢献する態勢を整えています。肥満は、体脂肪の異常な蓄積や過剰な蓄積を特徴とし、個人にかなりの健康リスクをもたらします。オメガ3処方薬は、肥満に関連する特定の状態を管理し、全体的な健康を増進する上で不可欠なツールとして機能し、それによって体重管理の努力を助ける。2022年3月に世界保健機関（WHO）が発表した報告書によると、現在、世界で10億人以上が肥満と分類されており、その内訳は成人6億5,000万人、青年3億4,000万人、小児3,900万人となっています。さらに、2025年までに、大人も子供も含めて推定1億6700万人が太りすぎや肥満のために健康状態が悪化すると予測され、厄介な傾向を示しています。その結果、肥満に悩む人口の増加が、オメガ3処方薬市場の成長軌道を支える原動力として浮上してくる。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界オメガ3処方薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のオメガ3処方薬市場：成長率分析
• 世界のオメガ3処方薬市場の実績：規模と成長, 2019-2024
• 世界のオメガ3処方薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界オメガ3処方薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のオメガ3処方薬市場薬の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヴァシェパ
• ロヴァザ
• その他のタイプ
• 世界のオメガ3処方薬市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 高トリグリセリド血症
• その他のアプリケーションタイプ
• 世界のオメガ3処方薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のオメガ3処方薬市場、Vascepaのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 純粋なEPA（エイコサペンタエン酸）配合
• 心血管リスク低減の適応症
• 世界のオメガ3処方薬市場、Lovazaのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• EPAとDHA（ドコサヘキサエン酸）の組み合わせ
• 高トリグリセリド血症管理の適応症
• 世界のオメガ3処方薬市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• エパノバ（オメガ3カルボン酸）
• 臨床試験におけるオメガ3製剤
• その他の処方オメガ3製品

第7章 地域別・国別分析

• 世界のオメガ3処方薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のオメガ3処方薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• オメガ3処方薬市場：競合情勢
• オメガ3処方薬市場：企業プロファイル
  • Ionis Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Sarepta Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • Alnylam Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • Wave Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • Dyno Therapeutics Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• BioNTech SE
• Moderna Therapeutics
• Silence Therapeutics
• Arrowhead Pharmaceuticals
• ProQR Therapeutics
• Regulus Therapeutics
• Stoke Therapeutics
• Editas Medicine
• Beam Therapeutics
• Miragen Therapeutics
• Biogen Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Arbutus Biopharma
• Sanofi S.A.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• オメガ3処方薬市場2029：新たな機会を提供する国
• オメガ3処方薬市場2029：新たな機会を提供するセグメント
• オメガ3処方薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Omega-3 prescription drugs work by reducing triglyceride levels in the bloodstream and increasing the levels of beneficial HDL cholesterol. These essential fatty acids, derived from food or supplements, play a crucial role in nurturing a healthy body and are integral in the construction of cell walls throughout the body.

Omega-3 prescription drugs primarily comprise vascepa, lovaza, and other variants. Vascepa specifically targets reducing heart attack, stroke, and select cardiovascular conditions requiring hospitalization in adults. Approved by the FDA, Vascepa aims to mitigate the risk of specific cardiovascular issues in adults with elevated triglyceride levels and multiple additional risk factors such as hypertension, high cholesterol, or obesity. These omega-3 prescription drugs find application in managing hypertriglyceridemia and various other conditions. Their distribution channels include hospital pharmacies, retail outlets, and online pharmacies.

The omega 3 prescription drugs market research report is one of a series of new reports from The Business Research Company that provides omega 3 prescription drugs market statistics, including omega 3 prescription drugs industry global market size, regional shares, competitors with an omega 3 prescription drugs market share, detailed omega 3 prescription drugs market segments, market trends and opportunities, and any further data you may need to thrive in the omega 3 prescription drugs industry. This omega 3 prescription drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The omega 3 prescription drugs market size has grown strongly in recent years. It will grow from $1.61 billion in 2024 to $1.76 billion in 2025 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to health awareness, clinical research, cardiovascular health emphasis, medical recommendations, chronic diseases management.

The omega 3 prescription drugs market size is expected to see rapid growth in the next few years. It will grow to $2.61 billion in 2029 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to expanded indications, evolving consumer preferences, targeted health solutions, personalized medicine, clinical evidence expansion. Major trends in the forecast period include personalized health solutions, expanded health conditions, innovative formulations, health supplement popularity, health apps and wearables.

The increasing prevalence of cardiovascular diseases (CVDs) is expected to boost the growth of the omega-3 prescription drug market. Elevated levels of blood triglycerides, a fatty substance, are associated with a higher risk of cardiovascular disorders, and omega-3 supplements can help regulate and lower these triglyceride levels. For example, the World Health Organization (WHO) reported in 2022 that cardiovascular diseases remained the leading cause of death globally, accounting for approximately 20.5 million deaths-almost a third of all fatalities worldwide. This marks an increase from the previously estimated 121 million deaths attributed to CVDs. As a result, the rising incidence of cardiovascular diseases is driving the expansion of the omega-3 prescription drug market.

The expanding population grappling with obesity stands poised to significantly contribute to the growth of the omega-3 prescription drug market. Obesity, characterized by an abnormal or excessive accumulation of body fat, poses considerable health risks to individuals. Omega-3 prescription drugs serve as essential tools in managing specific conditions associated with obesity and enhancing overall health, thereby aiding in weight management endeavors. A report from the World Health Organization (WHO) in March 2022 highlighted alarming statistics, indicating that over 1 billion individuals worldwide are presently classified as obese, comprising 650 million adults, 340 million adolescents, and 39 million children. Moreover, projections indicate a troubling trend, with an estimated 167 million individuals-both adults and children-expected to experience deteriorating health due to being overweight or obese by 2025. Consequently, the escalating population grappling with obesity emerges as a driving force behind the growth trajectory of the omega-3 prescription drug market.

The omega-3 prescription drug market is witnessing a surge in the adoption of new product innovations as a prominent trend. Leading companies engaged in the manufacturing of omega-3 drugs are strategically focusing on the development of novel products to fortify their market positions. A significant milestone occurred in October 2022 when the European Commission approved plant-based omega-3 products from DSM for use as substitutes for fish and animal-derived sources across the EU. DSM asserts that these products bolster the nutritional profile of plant-based foods while facilitating the creation of fish-such as products derived from animals. This omega-3 supplement serves as a means to augment the nutritional content of various goods without adversely impacting the marine ecosystem.

Major players within the omega-3 prescription drug market are strategically concentrating on product launches, particularly capsules designed to reduce the body's production of triglycerides. Capsules, recognized as pharmaceutical or dietary supplement dosage forms, feature a shell, usually composed of gelatin or a similar substance, encapsulating a precise quantity of medication, nutrients, or other active ingredients for convenient ingestion. A notable example occurred in March 2023 when Hikma Pharmaceuticals, a multinational pharmaceutical company headquartered in England specializing in generic and in-licensed pharmaceutical products, introduced the Icosapent Ethyl Capsules, 0.5g, in the US market. This product is specifically indicated for lowering triglyceride levels in adults afflicted with severe hypertriglyceridemia, containing eicosatetraenoic acid (EPA), acknowledged for its efficacy in reducing triglycerides. This launch marks an innovation in the market, catering to the needs of addressing severe hypertriglyceridemia and meeting the escalating demand for pharmaceutical-grade omega-3 products. It aligns harmoniously with the market's heightened focus on delivering effective therapies for conditions such as elevated triglyceride levels.

In July 2024, KD Pharma, a Europe-based contract development and manufacturing organization (CDMO) specializing in pharmaceutical and nutritional lipids, acquired DSM-Firmenich's MEG-3 fish oil business. This acquisition includes production facilities in Peru and Canada, as well as approximately 200 employees, for an undisclosed amount. This strategic move enables KD Pharma to enhance its presence in the food, beverage, dietary supplement, and pharmaceutical markets. The MEG-3 business, associated with omega-3 products, is part of DSM-Firmenich's operations.

Major companies operating in the omega 3 prescription drugs market include Ionis Pharmaceuticals, Sarepta Therapeutics, Alnylam Pharmaceuticals, Wave Life Sciences, Dyno Therapeutics, BioNTech SE, Moderna Therapeutics, Silence Therapeutics, Arrowhead Pharmaceuticals, ProQR Therapeutics, Regulus Therapeutics, Stoke Therapeutics, Editas Medicine, Beam Therapeutics, Miragen Therapeutics, Biogen Inc., Pfizer Inc., GlaxoSmithKline plc, Arbutus Biopharma, Sanofi S.A., Benitec Biopharma, CRISPR Therapeutics, Dicerna Pharmaceuticals, Translate Bio, PepGen Inc., Sirnaomics Inc., Sterna Biologicals, Genevant Sciences, Genzyme Corporation.

North America was the largest region in the omega 3 prescription drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the omega 3 prescription drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the omega 3 prescription drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The omega 3 prescription drugs market consists of sales of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Omega 3 Prescription Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on omega 3 prescription drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for omega 3 prescription drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The omega 3 prescription drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Vascepa; Lovaza; Other Type
• 2) By Application Type: Hypertriglyceridemia; Other Application Type
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Vascepa: Pure EPA (Eicosapentaenoic Acid) Formulation; Indications For Cardiovascular Risk Reduction
• 2) By Lovaza: Combination Of EPA And DHA (Docosahexaenoic Acid); Indications For Hypertriglyceridemia Management
• 3) By Other Types: Epanova (Omega-3 Carboxylic Acids); Omega-3 Formulations In Clinical Trials; Other Prescription Omega-3 Products
• Companies Mentioned: Ionis Pharmaceuticals; Sarepta Therapeutics; Alnylam Pharmaceuticals; Wave Life Sciences; Dyno Therapeutics
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Omega 3 Prescription Drugs Market Characteristics

3. Omega 3 Prescription Drugs Market Trends And Strategies

4. Omega 3 Prescription Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Omega 3 Prescription Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Omega 3 Prescription Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Omega 3 Prescription Drugs Market Growth Rate Analysis
• 5.4. Global Omega 3 Prescription Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Omega 3 Prescription Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Omega 3 Prescription Drugs Total Addressable Market (TAM)

6. Omega 3 Prescription Drugs Market Segmentation

• 6.1. Global Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vascepa
• Lovaza
• Other Type
• 6.2. Global Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hypertriglyceridemia
• Other Application Type
• 6.3. Global Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Omega 3 Prescription Drugs Market, Sub-Segmentation Of Vascepa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pure EPA (Eicosapentaenoic Acid) Formulation
• Indications For Cardiovascular Risk Reduction
• 6.5. Global Omega 3 Prescription Drugs Market, Sub-Segmentation Of Lovaza, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Of EPA And DHA (Docosahexaenoic Acid)
• Indications For Hypertriglyceridemia Management
• 6.6. Global Omega 3 Prescription Drugs Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Epanova (Omega-3 Carboxylic Acids)
• Omega-3 Formulations In Clinical Trials
• Other Prescription Omega-3 Products

7. Omega 3 Prescription Drugs Market Regional And Country Analysis

• 7.1. Global Omega 3 Prescription Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Omega 3 Prescription Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Omega 3 Prescription Drugs Market

• 8.1. Asia-Pacific Omega 3 Prescription Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Omega 3 Prescription Drugs Market

• 9.1. China Omega 3 Prescription Drugs Market Overview
• 9.2. China Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Omega 3 Prescription Drugs Market

• 10.1. India Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Omega 3 Prescription Drugs Market

• 11.1. Japan Omega 3 Prescription Drugs Market Overview
• 11.2. Japan Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Omega 3 Prescription Drugs Market

• 12.1. Australia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Omega 3 Prescription Drugs Market

• 13.1. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Omega 3 Prescription Drugs Market

• 14.1. South Korea Omega 3 Prescription Drugs Market Overview
• 14.2. South Korea Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Omega 3 Prescription Drugs Market

• 15.1. Western Europe Omega 3 Prescription Drugs Market Overview
• 15.2. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Omega 3 Prescription Drugs Market

• 16.1. UK Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Omega 3 Prescription Drugs Market

• 17.1. Germany Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Omega 3 Prescription Drugs Market

• 18.1. France Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Omega 3 Prescription Drugs Market

• 19.1. Italy Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Omega 3 Prescription Drugs Market

• 20.1. Spain Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Omega 3 Prescription Drugs Market

• 21.1. Eastern Europe Omega 3 Prescription Drugs Market Overview
• 21.2. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Omega 3 Prescription Drugs Market

• 22.1. Russia Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Omega 3 Prescription Drugs Market

• 23.1. North America Omega 3 Prescription Drugs Market Overview
• 23.2. North America Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Omega 3 Prescription Drugs Market

• 24.1. USA Omega 3 Prescription Drugs Market Overview
• 24.2. USA Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Omega 3 Prescription Drugs Market

• 25.1. Canada Omega 3 Prescription Drugs Market Overview
• 25.2. Canada Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Omega 3 Prescription Drugs Market

• 26.1. South America Omega 3 Prescription Drugs Market Overview
• 26.2. South America Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Omega 3 Prescription Drugs Market

• 27.1. Brazil Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Omega 3 Prescription Drugs Market

• 28.1. Middle East Omega 3 Prescription Drugs Market Overview
• 28.2. Middle East Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Omega 3 Prescription Drugs Market

• 29.1. Africa Omega 3 Prescription Drugs Market Overview
• 29.2. Africa Omega 3 Prescription Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Omega 3 Prescription Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Omega 3 Prescription Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Omega 3 Prescription Drugs Market Competitive Landscape And Company Profiles

• 30.1. Omega 3 Prescription Drugs Market Competitive Landscape
• 30.2. Omega 3 Prescription Drugs Market Company Profiles
  • 30.2.1. Ionis Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sarepta Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Alnylam Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Wave Life Sciences Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dyno Therapeutics Overview, Products and Services, Strategy and Financial Analysis

31. Omega 3 Prescription Drugs Market Other Major And Innovative Companies

• 31.1. BioNTech SE
• 31.2. Moderna Therapeutics
• 31.3. Silence Therapeutics
• 31.4. Arrowhead Pharmaceuticals
• 31.5. ProQR Therapeutics
• 31.6. Regulus Therapeutics
• 31.7. Stoke Therapeutics
• 31.8. Editas Medicine
• 31.9. Beam Therapeutics
• 31.10. Miragen Therapeutics
• 31.11. Biogen Inc.
• 31.12. Pfizer Inc.
• 31.13. GlaxoSmithKline plc
• 31.14. Arbutus Biopharma
• 31.15. Sanofi S.A.

32. Global Omega 3 Prescription Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Omega 3 Prescription Drugs Market

34. Recent Developments In The Omega 3 Prescription Drugs Market

35. Omega 3 Prescription Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Omega 3 Prescription Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Omega 3 Prescription Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Omega 3 Prescription Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer